NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
10.49
Dollar change
+1.33
Percentage change
14.52
%
Index- P/E- EPS (ttm)-5.77 Insider Own0.04% Shs Outstand27.34M Perf Week23.12%
Market Cap286.80M Forward P/E- EPS next Y-2.57 Insider Trans-8.35% Shs Float27.33M Perf Month25.63%
Enterprise Value286.19M PEG- EPS next Q-0.18 Inst Own42.51% Short Float0.08% Perf Quarter53.81%
Income-113.65M P/S- EPS this Y-116.31% Inst Trans38.68% Short Ratio0.24 Perf Half Y252.01%
Sales0.00M P/B74.94 EPS next Y-1.36% ROA-115.70% Short Interest0.02M Perf YTD239.48%
Book/sh0.14 P/C22.13 EPS next 5Y12.64% ROE-198.47% 52W High12.78 -17.92% Perf Year147.43%
Cash/sh0.47 P/FCF- EPS past 3/5Y12.94% 24.05% ROIC-1209.32% 52W Low2.20 375.84% Perf 3Y-58.04%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.08% 7.15% Perf 5Y-80.75%
Dividend TTM- EV/Sales- EPS Y/Y TTM-38.74% Oper. Margin- ATR (14)0.80 Perf 10Y-96.18%
Dividend Ex-Date- Quick Ratio0.72 Sales Y/Y TTM- Profit Margin- RSI (14)61.33 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio0.72 EPS Q/Q7.19% SMA2016.12% Beta-0.59 Target Price18.52
Payout- Debt/Eq4.30 Sales Q/Q- SMA5013.27% Rel Volume0.72 Prev Close9.16
Employees109 LT Debt/Eq2.28 EarningsApr 30 AMC SMA20092.53% Avg Volume89.84K Price10.49
IPOOct 22, 2014 Option/ShortNo / Yes EPS/Sales Surpr.-8.33% 60.00% Trades Volume64,753 Change14.52%
Date Action Analyst Rating Change Price Target Change
May-29-25Resumed Goldman Sell $7.25
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jun-25-25 04:15PM
Jun-23-25 09:40AM
09:40AM
09:40AM
09:40AM
09:40AM Loading…
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
Jun-12-25 04:05PM
Jun-11-25 04:30PM
Jun-04-25 04:32PM
Jun-03-25 04:30PM
May-21-25 09:40AM
12:00PM Loading…
May-16-25 12:00PM
08:50AM
May-15-25 04:30PM
May-06-25 04:30PM
May-05-25 04:30PM
Apr-30-25 04:00PM
08:50AM
06:25AM
Apr-14-25 08:50AM
Apr-11-25 04:30PM
Apr-10-25 07:00AM
Mar-27-25 10:30PM
Mar-24-25 03:09AM
02:30AM
Feb-25-25 04:01PM
04:05PM Loading…
Jan-13-25 04:05PM
Jan-08-25 04:05PM
Dec-12-24 09:59AM
Dec-11-24 04:05PM
Dec-02-24 04:30PM
Nov-11-24 04:30PM
Nov-06-24 04:30PM
Oct-24-24 08:31AM
Oct-22-24 04:45PM
Oct-18-24 04:30PM
Oct-14-24 04:30PM
Sep-23-24 04:30PM
Sep-04-24 04:30PM
Aug-02-24 04:30PM
Jul-30-24 08:55PM
05:30PM
04:30PM
Jul-29-24 01:30AM
Jul-08-24 04:30PM
Jun-05-24 04:30PM
Jun-04-24 04:30PM
May-31-24 09:51AM
May-30-24 04:30PM
May-17-24 04:30PM
May-16-24 04:30PM
May-09-24 04:30PM
May-07-24 11:53PM
04:30PM
Apr-25-24 04:30PM
Apr-04-24 04:43PM
Mar-08-24 11:01AM
09:33AM
Mar-07-24 10:52PM
04:30PM
Mar-04-24 04:30PM
Feb-20-24 04:30PM
Jan-16-24 04:30PM
Dec-04-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 04:30PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Oct-27-23 04:30PM
Oct-16-23 02:00AM
Oct-05-23 04:30PM
Sep-05-23 04:30PM
Jul-31-23 04:25PM
Jul-25-23 04:30PM
Jul-19-23 04:30PM
Jul-10-23 04:30PM
Jun-16-23 04:30PM
Jun-08-23 04:30PM
Jun-06-23 05:00PM
May-10-23 05:30PM
May-09-23 04:30PM
May-04-23 04:30PM
Apr-19-23 05:09PM
Apr-12-23 04:30PM
Mar-24-23 04:30PM
Mar-13-23 01:30AM
Mar-07-23 04:30PM
Mar-02-23 05:30PM
04:30PM
Feb-27-23 01:30AM
Feb-21-23 04:30PM
Feb-10-23 04:30PM
Jan-23-23 04:30PM
Jan-04-23 04:30PM
Dec-23-22 01:30AM
Dec-08-22 04:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohideen PharisChief Medical OfficerMay 22 '25Sale1.84397730110,113May 27 04:10 PM
Mohideen PharisChief Medical OfficerJan 30 '25Sale0.85600510110,510Jan 31 04:59 PM
Mohideen PharisChief Medical OfficerNov 25 '24Sale0.57565322111,110Nov 27 04:15 PM
Mohideen PharisChief Medical OfficerNov 22 '24Sale0.53342181111,675Nov 27 04:15 PM
Mohideen PharisChief Medical OfficerNov 21 '24Sale0.542,3501,269112,017Nov 25 05:13 PM
Mohideen PharisChief Medical OfficerJul 29 '24Sale0.981,7851,74979,367Jul 31 05:32 PM